Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06982131
Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis
- Conditions
- Bacterial VaginosisCandida Vaginitis
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06975436
- Locations
- 🇺🇸
Matrix Clinical Research, Los Angeles, California, United States
🇺🇸M3 Wake Research - San Diego at Convoy, San Diego, California, United States
🇺🇸Red Rocks OBGYN, Lakewood, Colorado, United States
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
- Conditions
- ObesityOverweightOverweight With One Weight Related Comorbidity
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 234
- Registration Number
- NCT06965413
- Locations
- 🇺🇸
Juno Research, LLC, Houston, Texas, United States
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Geographic AtrophyAge-related Macular Degeneration
- Interventions
- Drug: RO7669330Drug: Syfovre™Drug: Izervay™
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT06961370
- Locations
- 🇺🇸
Global Research Management, Glendale, California, United States
🇺🇸Southeast Retina Center, Augusta, Georgia, United States
🇺🇸Erie Retina Research, Erie, Pennsylvania, United States
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT06934044
- Locations
- 🇨🇳
Tianjin Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06903065
- Locations
- 🇺🇸
Adobe Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Premier Medical Group Int Medcn, Clarksville, Tennessee, United States
🇺🇸DHR Health Institute for Research and Development, Edinburg, Texas, United States
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06809608
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
- Conditions
- Neoplasms
- Interventions
- Drug: RO7673396
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 345
- Registration Number
- NCT06884618
- Locations
- 🇳🇿
New Zealand Clinical Research - Auckland, Auckland, New Zealand
🇳🇿New Zealand Clinical Research - Christchurch, Christchurch, New Zealand
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Drug: Von Willebrand Factor ConcentratesDrug: Von Willebrand Factor Concentrates and Factor VIII ConcentratesDrug: Factor VIII ConcentratesDrug: Recombinant Activated Factor VII
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06883240
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇮🇹Universita' Degli Studi La Sapienza-Ist.Di Ematologia, Roma, Lazio, Italy
🇮🇹AOU Careggi, Firenze, Toscana, Italy
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT06880328
- Locations
- 🇺🇸
Parexel California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Collaborative Neuroscience Network Inc., Torrance, California, United States
🇺🇸CBH Health, Gaithersburg, Maryland, United States